Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eurand, a specialty pharmaceutical company, has signed three new commercialization, license and supply agreements for its novel extended-release formulation of the muscle relaxant cyclobenzaprine HCl. Financial terms were not disclosed.
Subscribe to our email newsletter
The company has partnered with Nobel Ilac for Turkey, PharmaSwiss for Israel and Adcock Ingram for South Africa for commercializing the product, subject to regulatory review and approval, in the respective countries.
As announced in August 2008, Eurand signed a licensing and supply agreement with Daewoong Pharmaceuticals, a South Korean pharmaceutical company. Under terms of the agreement, Daewoong will commercialize cyclobenzaprine extended-release (ER) in South Korea, subject to regulatory approval.
Developed using Eurand’s Diffucaps technology, cyclobenzaprine ER is a centrally acting muscle relaxant indicated as an adjunct to rest for the relief of muscle spasm associated with acute, painful musculoskeletal conditions. Cephalon markets the product in the US under the brand name Amrix.
Cyclobenzaprine ER is available for licensing in certain other countries.
John Fraher, Eurand’s chief commercial officer, said: “These agreements represent important milestones in expanding Eurand’s cyclobenzaprine ER franchise into new territories.”